FDA 483 - Abraxis Bioscience, LLC - April 06, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Abraxis Bioscience, LLC in Phoenix, AZ, revealed significant deficiencies in their quality system and aseptic processing. The firm failed to thoroughly investigate media fill failures and released drug product manufactured under processes that were not adequately evaluated. Additionally, procedures to prevent microbiological contamination of sterile drug products were not properly established or followed, particularly concerning personnel sampling during aseptic operations.
ID · 250f83a6-29ae-4dc6-98ec-9e1f3087c8a8